BACKGROUND AND METHODS. Physicians have long believed that the erythrocyte sedimentation rate is low in patients with congestive heart failure, but this concept is based on a misinterpretation of the results in a single report published in 1936. To reevaluate this concept in the modern era, we measured the sedimentation rate in 242 patients who were referred for treatment of chronic heart failure. RESULTS. The sedimentation rate was low (less than 5 mm per hour) in only 24 patients (10 percent) but was increased (above 25 mm per hour) in 50 percent. Patients with low or normal sedimentation rates (less than or equal to 25 mm per hour) had more severe hemodynamic abnormalities than patients with elevated rates: lower cardiac index (mean +/- SEM, 1.7 +/- 0.1 vs. 2.0 +/- 0.1 liters per minute per square meter of body-surface area) and higher mean right atrial pressure (mean +/- SEM, 12 +/- 1 vs. 9 +/- 1 mm Hg) (both P less than 0.0001). New York Heart Association functional class IV symptoms were present in 66 percent of the patients with a low or normal sedimentation rate, as compared with 42 percent of those with elevated rates (P less than 0.0001). After one to three months of therapy, patients whose sedimentation rates decreased showed little hemodynamic or clinical response to treatment, whereas both cardiac performance and functional status improved in patients whose rates increased (P less than 0.02 for the comparison between groups). The sedimentation rate was correlated with the plasma fibrinogen level (r = 0.64, P = 0.0025), and changes in the sedimentation rate during treatment were correlated inversely with changes in mean right atrial pressure (r = -0.57, P = 0.0002). During long-term follow-up, patients with low or normal sedimentation rates had a worse one-year survival than patients with elevated rates (41 vs. 66 percent, P = 0.01). CONCLUSIONS. These data indicate that the erythrocyte sedimentation rate is correlated with the severity of illness in patients with chronic heart failure. Because of its lack of discriminatory power, however, the test is of limited value in the clinical management of this disorder.
Source Information
Department of Medicine, Mount Sinai School of Medicine, New York, NY 10029.
This article has been cited by other articles:
Christen, A., Efstathiadou, Z., Laspa, E., Johnston, D. G., Godsland, I. F.
(2007). Rate of Change and Instability in Body Mass Index, Insulin Resistance, and Lipid Metabolism as Predictors of Atherosclerotic Vascular Disease. J. Clin. Endocrinol. Metab.
92: 3780-3787
[Abstract][Full Text]
Maradit-Kremers, H, Nicola, P J, Crowson, C S, Ballman, K V, Jacobsen, S J, Roger, V L, Gabriel, S E
(2007). Raised erythrocyte sedimentation rate signals heart failure in patients with rheumatoid arthritis. Ann Rheum Dis
66: 76-80
[Abstract][Full Text]
Menezes Falcao, L., Pinto, F., Ravara, L., van Zwieten, P. A.
(2004). BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction. Journal of Renin-Angiotensin-Aldosterone System
5: 121-129
[Abstract]
Henry, D. H., Bowers, P., Romano, M. T., Provenzano, R.
(2004). Epoetin Alfa: Clinical Evolution of a Pleiotropic Cytokine. Arch Intern Med
164: 262-276
[Abstract][Full Text]
Malhotra, A., Muse, V. V., Mark, E. J.
(2003). Case 12-2003 - An 82-Year-Old Man with Dyspnea and Pulmonary Abnormalities. NEJM
348: 1574-1585
[Full Text]
Mancini, D. M., Katz, S. D., Lang, C. C., LaManca, J., Hudaihed, A., Androne, A.-S.
(2003). Effect of Erythropoietin on Exercise Capacity in Patients With Moderate to Severe Chronic Heart Failure. Circulation
107: 294-299
[Abstract][Full Text]
McClellan, W. M., Flanders, W. D., Langston, R. D., Jurkovitz, C., Presley, R.
(2002). Anemia and Renal Insufficiency Are Independent Risk Factors for Death among Patients with Congestive Heart Failure Admitted to Community Hospitals: A Population-Based Study. J. Am. Soc. Nephrol.
13: 1928-1936
[Abstract][Full Text]
Al-Ahmad, A., Rand, W. M., Manjunath, G., Konstam, M. A., Salem, D. N., Levey, A. S., Sarnak, M. J.
(2001). Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction. J Am Coll Cardiol
38: 955-962
[Abstract][Full Text]
Silverberg, D. S., Wexler, D., Sheps, D., Blum, M., Keren, G., Baruch, R., Schwartz, D., Yachnin, T., Steinbruch, S., Shapira, I., Laniado, S., Iaina, A.
(2001). The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J Am Coll Cardiol
37: 1775-1780
[Abstract][Full Text]
Sharma, R., Rauchhaus, M., Ponikowski, P. P., Varney, S., Poole-Wilson, P. A., Mann, D. L., Coats, A. J. S., Anker, S. D.
(2000). The relationship of the erythrocyte sedimentation rate to inflammatory cytokines and survival in patients with chronic heart failure treated with angiotensin-converting enzyme inhibitors. J Am Coll Cardiol
36: 523-528
[Abstract][Full Text]
Silverberg, D. S., Wexler, D., Blum, M., Keren, G., Sheps, D., Leibovitch, E., Brosh, D., Laniado, S., Schwartz, D., Yachnin, T., Shapira, I., Gavish, D., Baruch, R., Koifman, B., Kaplan, C., Steinbruch, S., Iaina, A.
(2000). The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol
35: 1737-1744
[Abstract][Full Text]
Greeno, E. W., Glaser, R. J., Papagiannis, A., Lucey, C. R., Kopp, V. J., Rozenman, Y., Gilon, D., Fuchs, S.
(1997). Clinical Problem-Solving -- Where Did Good Old Clinical Diagnosis Go?. NEJM
337: 940-942
[Full Text]
Babich, D. J., Baker, D. W., Aiia, B. J., Morales, J., Martinez, M.-T., Thibault, G. E.
(1996). Clinical Problem-Solving: Mitral Stenosis -- Silent?. NEJM
334: 57-58
[Full Text]
Packer, M.
(1995). Is Tumor Necrosis Factor an Important Neurohormonal Mechanism in Chronic Heart Failure?. Circulation
92: 1379-1382
[Full Text]
